# Filing Detail

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-20-002578
Filing Date
2020-10-09
Accepted
2020-10-09 17:20:16
Documents
2

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | AMENDMENT NO. 7 TO THE SCHEDULE 13D | sc13da707422xoma_10092020.htm | SC 13D/A | 302306
2 | EXHIBIT 99.1 - SECURITIES PURCHASE PLAN AGREEMENT | ex991to13da707422xoma_100920.pdf | SC 13D/A | 3095591
| Complete submission text file | 0000921895-20-002578.txt |  | 4552394

Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Corp (Subject) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-38028 | Film No.: 201233967
SIC: 2834 Pharmaceutical Preparations

Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

EIN.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice